Valuation
- Market cap
- 6,393,000
- Revenue TTM
- $1,104,000
- Net income TTM
- $-90,288,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -8,178.26%
- Debt to equity
- 0.52
Trading
- Volume
- 2,500
- Avg volume
- 2,172
- Day's range
- $0.00 – $0.00
- Shares out
- 42,623,000
- Stochastic %K
- 50%
- Beta
- -0.06
- Analysts
- Hold
- Price target
- $11.85
Company profile
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic...
Show more
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 674 9000
- Website
- https://kaleido.com
- Address
- 65 Hayden Avenue, Lexington, United States
Latest news
No headlines yet.
